Literature DB >> 26889240

Clinicopathological observation of primary lung enteric adenocarcinoma and its response to chemotherapy: A case report and review of the literature.

L I Lin1, Chun-Wei Xu2, B O Zhang2, Rong-Rui Liu1, Fei-Jiao Ge1, Chuan-Hua Zhao1, R U Jia1, Quan-Hong Qin3, Jelena Stojsic4, Yan Wang1, Jian-Ming Xu1.   

Abstract

Primary lung enteric adenocarcinoma is a rare type of invasive lung carcinoma. Its morphology and immunohistochemistry are those of colorectal carcinoma, but there is no associated primary colorectal carcinoma. The present study describes the case of a 53-year-old female who presented with an irritating cough and a mass around the right sternoclavicular joint. Comprehensive evaluation revealed involvement of the mediastinum, lungs, right sternoclavicular joint and right kidney. Biopsies from the mediastinal and right sternoclavicular joint tumors showed features of adenocarcinoma. Immunohistochemistry was positive for cytokeratin (CK)20 and caudal type homeobox transcription factor 2, and negative for CK7, thyroid transcription factor-1 and napsin A. Genotypic analysis identified the expression of wild-type epidermal growth factor receptor, Kirsten rat sarcoma viral oncogene homolog, serine/threonine-protein kinase B-Raf and UDP-glucuronosyltransferase 1-1. There was no expression of echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase and a moderate expression of excision repair cross-complementation group 1, ribonucleoside-diphosphate reductase large subunit and tubulin β-3 chain. A strong expression of thymidylate synthase and 677TC genotype expression of methylenetetrahydrofolate reductase was observed. Gastroscopy, enteroscopy, colorectal colonoscopy and positron emission tomography-computed tomography failed to find evidence of a gastrointestinal malignancy and primary lung enteric adenocarcinoma was diagnosed. The presence of multiple metastases did not permit curative surgery. The patient was treated with 3 monthly cycles of the XELOX chemotherapy regimen; the response was poor with progression of supraclavicular lesions. Treatment was switched to the TP regimen for 4 monthly cycles, which resulted in a significant reduction in the size of the lung lesions; however, the supraclavicular lesion responded poorly to the treatment. The patient then received 2 cycles of the FOLFIRI regimen; however, the lung and right supraclavicular lesions progressed, causing increased right upper limb pain. The pain was alleviated by palliative surgery. Following surgery, the DP regimen was employed. Follow-up of the patient remains ongoing. The present findings suggest that the early diagnosis and treatment of primary lung enteric adenocarcinoma is likely to improve patient outcome.

Entities:  

Keywords:  chemotherapy; clinicopathogical; diagnosis; primary lung intestinal adenocarcinoma

Year:  2015        PMID: 26889240      PMCID: PMC4726875          DOI: 10.3892/etm.2015.2864

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  32 in total

1.  Primary pulmonary adenocarcinoma with enteric differentiation resembling metastatic colorectal carcinoma: a report of the second case negative for cytokeratin 7.

Authors:  Kazuhito Hatanaka; Koji Tsuta; Katsuya Watanabe; Keishi Sugino; Toshimasa Uekusa
Journal:  Pathol Res Pract       Date:  2010-08-19       Impact factor: 3.250

2.  Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens.

Authors:  D C Chhieng; J F Cangiarella; M F Zakowski; S Goswami; J M Cohen; H T Yee
Journal:  Cancer       Date:  2001-10-25       Impact factor: 6.860

3.  The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.

Authors:  L Bonanno; C Costa; M Majem; A Favaretto; M Rugge; R Rosell
Journal:  Ann Oncol       Date:  2013-02-20       Impact factor: 32.976

4.  DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Authors:  Ken A Olaussen; Ariane Dunant; Pierre Fouret; Elisabeth Brambilla; Fabrice André; Vincent Haddad; Estelle Taranchon; Martin Filipits; Robert Pirker; Helmut H Popper; Rolf Stahel; Laure Sabatier; Jean-Pierre Pignon; Thomas Tursz; Thierry Le Chevalier; Jean-Charles Soria
Journal:  N Engl J Med       Date:  2006-09-07       Impact factor: 91.245

5.  Pulmonary intestinal-type adenocarcinoma does not show enteric differentiation by immunohistochemical study.

Authors:  Samuel A Yousem
Journal:  Mod Pathol       Date:  2005-06       Impact factor: 7.842

6.  Two different types of carcinoid tumors of the lung: immunohistochemical and ultrastructural investigation and their histogenetic consideration.

Authors:  Kyung-Whan Min
Journal:  Ultrastruct Pathol       Date:  2013-02       Impact factor: 1.094

7.  Enteric adenocarcinoma lung: a rare presentation in an Omani woman.

Authors:  Asim Qureshi; Muhammad Furrukh
Journal:  BMJ Case Rep       Date:  2013-01-25

8.  A phase II trial and pharmacokinetic analysis of 96-hour infusional paclitaxel in patients with metastatic colorectal cancer.

Authors:  K Huang; D J Vaughn; L M Shaw; A Recio; H S Bonner; D G Haller
Journal:  Am J Clin Oncol       Date:  1998-12       Impact factor: 2.339

9.  Pulmonary enteric adenocarcinoma: a study of the clinicopathologic and molecular status of nine cases.

Authors:  Cai-Xia Wang; Biao Liu; Yan-Fen Wang; Ru-Song Zhang; Bo Yu; Zhen-Feng Lu; Qun-Li Shi; Xiao-Jun Zhou
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

10.  Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma.

Authors:  T Ueno; S Linder; G Elmberger
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

View more
  3 in total

1.  Combination of Pembrolizumab With Platinum-containing Chemotherapy for Pulmonary Enteric Adenocarcinoma.

Authors:  Shuhei Teranishi; Chihiro Sugimoto; Hirokazu Nagayama; Wataru Segawa; Atsushi Miyasaka; Shuntaro Hiro; Chihiro Maeda; Hironori Tamura; Nami Masumoto; Yoshinori Nagahara; Nobuyuki Hirama; Nobuaki Kobayashi; Masaki Yamamoto; Makoto Kudo; Takeshi Kaneko
Journal:  Cancer Diagn Progn       Date:  2022-03-03

2.  Distinctive features of immunostaining and mutational load in primary pulmonary enteric adenocarcinoma: implications for differential diagnosis and immunotherapy.

Authors:  Ming Chen; Pu Liu; Feifei Yan; Suzhen Xu; Qi Jiang; Jingying Pan; Mengye He; Peng Shen
Journal:  J Transl Med       Date:  2018-03-27       Impact factor: 5.531

3.  Hyperprogressive Disease After Immunotherapy: A Case Report of Pulmonary Enteric Adenocarcinoma.

Authors:  Chun-Hong Hu; Shenghao Shi; Wen Dong; Lizhi Xiao; Hongjing Zang; Fang Wu
Journal:  Front Oncol       Date:  2022-03-07       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.